knowledge -WSS

knowledge

author：Wikipedia 2025-08-12 09:09:15 - browse：165

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

explore

WSS

Vaccine advisory panel ACIP left half staffed by HHS

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

To avoid data mishandling cases, universities eye AI and other tools

What we’ve learned from the Aduhelm mess

It's time to retire 'poor historian' from clinicians' vocabularies

Helping hospitals and community health centers plan for resilience

knowledge

knowledge

focus

Jerome Adams on the need for new antivirals for Covid

Medicare threatens to cut off funding for HCA's Mission hospital

As demand for Covid shots wanes, Moderna seeks its next success

Readers respond to H5N1 and livestock movements, and more

ChatGPT in medicine: STAT answers readers' burning questions

How digital tools helped lower hypertension in marginalized patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

It's time to retire 'poor historian' from clinicians' vocabularies

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readers respond to H5N1 and livestock movements, and more

knowledge

Biogen Alzheimer’s drug launch off to slow start

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Cytokinetics CEO stresses company can launch heart drug on its own

Helping hospitals and community health centers plan for resilience

Robert F. Kennedy is pitching centrism on health, even on abortion

Robert F. Kennedy is pitching centrism on health, even on abortion

leisure time

leisure time

explore

hotspot